QUIXIN
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
Aug 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QUIXIN is an ophthalmic solution approved in 2000 for eye infections and inflammatory conditions. The product is a small-molecule therapeutic delivered as topical drops. Specific mechanism of action and indications are not fully specified in available data.
LOE Approaching
With LOE approaching, the commercial team faces defensive positioning; expect headcount stabilization and focus on retention strategies rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
QUIXIN presents 79 linked career opportunities with strong representation in Manufacturing, Regulatory Affairs, and Commercial roles, reflecting a mature product requiring operational excellence and defensive market management. Geographic distribution spans Asia-Pacific and EMEA, indicating Santen's regional focus on this ophthalmic asset.
[Singapore] Global Safety Vigilance Risk Management Lead
Worked on QUIXIN at Santen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.